Protara Therapeutics, Inc. · NASDAQ:TARA
Protara Therapeutics — ASCO Genitourinary (GU) Cancers Symposium 2026
19 slides from Protara Therapeutics's conference presentation, Feb 24, 2026
Slide 1: Interim Data Presentation from the ADVANCED-2 Trial of TARA-002 in NMIBC
Interim Data Presentation from the ADVANCED - 2 Trial of TARA - 002 in Patients with NMIBC American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium February 2026
Slide 2: Forward-looking statements
2 Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “con
Slide 3: Agenda
Jesse Shefferman Co - founder, Director, Chief Executive Officer Neal Shore, MD Medical Director, START Carolinas/Carolina Urologic Research Center Introduction Jesse Shefferman Review of Updated TARA - 002 Data Carla Beckham, MD, PhD KOL Discussion Neal Shore, MD Closing Remarks Jesse Shefferman ǪG
Slide 4: Key Clinical Updates in NMIBC
Key Clinical Updates TARA - 002 in NMIBC • No additional administration procedures or safety protocols required • Rapid administration typically performed by nurse 3. Next steps • Expect to complete enrollment in the BCG - Unresponsive registrational cohort of ADVANCED - 2 in 2H’26 • Expect to initi
Slide 5: Diversified Late-Stage Pipeline
*Currently in pre - clinical studies to define dosing and, once protocol is confirmed, expect to initiate P2 trial cohort. **IV Choline granted Orphan Drug Designations by the U.S. FDA for the prevention and/or treatment of choline deficiency in patients on long - term PN and Fast Track Designation
Slide 6: Target Product Profile Sits at the Intersection NMIBC Patients and Urologists Prioritize
Safety G Tolerability Efficacy and Durability Ease - of - Use • Mild, self - limited local AEs • Predictable, well - characterized safety profile • Robust single agent activity • Competitive CR rates • Encouraging durability • Simple office - based intravesical instillation • No special handling req
Slide 7: ADVANCED-2 Results
ADVANCED - 2 RESULTS
Slide 8: TARA-002: A Unique TLR2/NOD2 Agonist Derived from Streptococcus Pyogenes
TARA - 002 ignites both innate and adaptive immunity through dual TLR2/NOD2 activation, driving potent local anti - tumor / cystic responses via fully inactivated bacteria (1)(2)(3) 8 1 Fujimoto T., et al. J Immunol. 1997: 5619; 2 Ryoma Y, et al. Anticancer Res. 2004; 3295 - 3298; 3 Zhao H, et al. M
Slide 9: ADVANCED-2 Registrational Design
Abbreviations: CR = complete response; CIS = carcinoma in situ *Aligned with the FDA’s 2024 BCG Unresponsive NMIBC: Developing Drugs and Biologics for Treatment Guidance for Industry. **Enrollment complete †Residual CIS and/or recurrence of HGTa; ^3 weekly instillations every 3 months through month
Slide 10: 68% CR at 6 Months with Durable Response Among BCG-Unresponsive Participants
Abbreviations: CR = complete response High - grade CR is based on central pathology including a mandatory biopsy at Month 3 Notes: Evaluable participants include those who had at least one dose of study drug before the response assessment time point and completed at least one response assessment; CR
Slide 11: Monotherapy Demonstrates 67% CR at 6 Months Among BCG-Naive Participants
TARA - 002 Monotherapy Demonstrates 67% CR at 6 Months with Durable Response Among BCG - Naïve Participants High - grade CR rate at any time (%) 72.4% 100 21 of 29 80 60 40 20 0 N = 2G High - grade CR rate (%) Landmark 66.7 (18 of 27) Month 6 57.G (11 of 19) Month 12 66.6 (4 of 6) Reinduction Salvag
Slide 12: Favorable Safety and Tolerability Profile with No Grade 3 or Greater TRAEs
Grade 4/5 Grade 3 Grade 2 Grade 1 Any Grade N = 74 0 0 4 (5) 19 (26) 19 (26) TRAEs, n (%) TRAEs ≥5%, n (%) 0 0 0 10 (14) 10 (14) Dysuria 0 0 3 (4) 4 (5) 7 (9) Bladder spasm 0 0 1 (1) 4 (5) 5 (7) Fatigue 0 0 0 4 (5) 4 (5) Micturition urgency 1 (1) 10 (14) 3 (4) 0 11 (15) SAEs, n (%) 0 0 0 0 0 Related
Slide 13: KOL Discussion
KOL DISCUSSION Neal Shore, MD Medical Director, START Carolinas/Carolina Urologic Research Center
Slide 14: Closing Remarks
o 6 © © © © © © © © © CLOSING REMARKS
Slide 15: Q&A
ǪCA Jesse Shefferman Co - founder, Director, Chief Executive Officer Jacqueline Zummo, PhD Co - founder, Senior Vice President, Chief RCD Officer © 2026 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute. | 15 Neal Shore, MD Medical Director, START Carolinas/ Carolina Urologic Res
Slide 16: Thank You
THANK YOU CU Srota RA THERAPEUTICS
Slide 17: Appendix
APPENDIX RAN SN NAAN NIN M7) Q = IS SRARE SSQy SN S \ SSS ~ SN N SSN SARK EAN SQW OSs SS MWY N ‘ YY ON eye Se Se) 066 Pee ees ies eoccee ee ooee ee? g 0002946 Q ° ve oe a ° g°S 0? . oe Oo %,
Slide 18: BCG-Unresponsive Cohort Demographics and Baseline Characteristics
Cohort B N = 43 Baseline Demographics Age (years) 75 (47, 92) Median (Min, Max) Sex, n (%) 31 (72.1) Male 12 (27.9) Female Race, n (%) 5 (11.6) Asian 1 (2.3) Black or African American 35 (81.4) White 1 (2.3) Other 1 (2.3) Not Reported BCG - Unresponsive Cohort Demographics and Baseline Characteristi
Slide 19: BCG-Naive Cohort Demographics and Baseline Characteristics
Cohort A N = 31 Baseline Demographics Age (years) 71 (45, 89) Median (Min, Max) Sex, n (%) 25 (80.6) Male 6 (19.4) Female Race, n (%) 1 (3.2) Black or African American 29 (93.5) White 1 (3.2) Not Reported BCG - Naïve Cohort Demographics and Baseline Characteristics © 2026 Protara Therapeutics. All R
Protara Therapeutics — ASCO Genitourinary (GU) Cancers Symposium 2026 on 6ix